Estimation of the socio-economic burden of obesity in the Russian Federation
Authors:
- L. Yu. GorbachenkoLGL. Yu. Gorbachenko
- K. I. MatreninKMK. I. Matrenin
- A. A. SlabikovaASA. A. Slabikova
- R. A. TeryanRTR. A. Teryan
- D. N. PustovalovDPD. N. Pustovalov
- N. S. GiliazetdinovaNGN. S. Giliazetdinova
- I. A. MikhailovIMI. A. Mikhailov
- U. N. DmitrievaUDU. N. Dmitrieva
- N. E. UsachevaNUN. E. Usacheva
- O. S. GolikovaOGO. S. Golikova
- V. I. SamokhatkaVSV. I. Samokhatka
- V. O. OzgeldiVOV. O. Ozgeldi
Open Access
- 19 August 2026
- journal article
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Abstract
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.Keywords
This publication has 16 references indexed in Scilit:
- Long-term dynamics of the prevalence of childhood and adolescent obesity in Russia and the worldObesity and metabolism, 2025
- Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in ChinaDiabetes, Obesity and Metabolism, 2025
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US AdultsJAMA Health Forum, 2025
- Cost-effectiveness analysis of bariatric surgery in obese patientsMedical Technologies. Assessment and Choice, 2025
- Prevalence of complications and co‐morbidities in males and females with obesity: Real‐world insights from claims data analysisDiabetes, Obesity and Metabolism, 2024
- Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022Diabetes mellitus, 2023
- Clinical and economic analysis of bariatric interventions in the treatment of obesity in the Russian FederationEndoscopic Surgery, 2023
- Fighting obesity as a direction of national health care developmentObesity and metabolism, 2022
- The prevalence of obesity in the adult population of the Russian Federation (literature review)Obesity and metabolism, 2022
- TWENTY YEARS TRENDS OF OBESITY AND ARTERIAL HYPERTENSION AND THEIR ASSOCIATION IN RUSSIACardiovascular Therapy and Prevention, 2017